PROMACTA Drug Insight and Market Forecast - 2032

“"PROMACTA Drug Insight and Market Forecast - 2032" ” report provides comprehensive insights about PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets. A detailed picture of the PROMACTA for ITP in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the PROMACTA for ITP. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PROMACTA market forecast analysis for ITP in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ITP.

Drug Summary:

PROMACTA (eltrombopag) tablets contain eltrombopag olamine, small molecule thrombopoietin (TPO) receptor agonist for oral administration. This is marketed under the brand name PROMACTA in the US and Revolade in most countries outside the US. This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic ITP or who have chronic hepatitis C. It may also treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Dosage

Persistent or chronic ITP: Initiate PROMACTA at 50 mg once daily for most adult and pediatric patients 6 years and older and at 25 mg once daily for pediatric patients aged 1-5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 × 109/L. Do not exceed 75 mg per day.

Mechanism of action

Eltrombopag is an orally bioavailable, small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cell.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the PROMACTA description, mechanism of action, dosage and administration, research and development activities in immune thrombocytopenic purpura (ITP).
• Elaborated details on PROMACTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the PROMACTA research and development activities in ITP across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around PROMACTA.
• The report contains forecasted sales of PROMACTA for ITP till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ITP.
• The report also features the SWOT analysis with analyst views for PROMACTA in ITP.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

PROMACTA Analytical Perspective by DelveInsight

In-depth PROMACTA Market Assessment

This report provides a detailed market assessment of PROMACTA for immune thrombocytopenic purpura (ITP) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

PROMACTA Clinical Assessment

The report provides the clinical trials information of PROMACTA for ITP covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for immune thrombocytopenic purpura (ITP) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence PROMACTA dominance.
• Other emerging products for ITP are expected to give tough market competition to PROMACTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of PROMACTA in ITP.
• Our in-depth analysis of the forecasted sales data of PROMACTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PROMACTA in ITP.

Key Questions:

• What is the product type, route of administration and mechanism of action of PROMACTA?
• What is the clinical trial status of the study related to PROMACTA in immune thrombocytopenic purpura (ITP) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the PROMACTA development?
• What are the key designations that have been granted to PROMACTA for ITP?
• What is the forecasted market scenario of PROMACTA for ITP?
• What are the forecasted sales of PROMACTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to PROMACTA for ITP?
• Which are the late-stage emerging therapies under development for the treatment of ITP?